Literature DB >> 8305837

Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy.

S Zierz1, R Schröder, C J Unkrig.   

Abstract

Five patients with various clinical and genetic phenotypes of adrenoleukodystrophy were treated with a diet enriched with glycerol trioleate and glycerol trierucate (GTE). In all patients platelet counts decreased upon the administration of GTE, but no bleeding symptoms occurred in any of the patients, and bleeding time remained normal. Pseudothrombocytopenia was excluded in all patients. Thrombocytopenia was marked (84,000-37,000/mm) in three of the patients but was fully reversible after discontinuation of GTE. Mean platelet volumes were abnormally increased in all patients. When GTE was again administered by stepwise increasing the daily dose, platelet counts showed a clearly dose-dependent decrease. Bone marrow biopsies revealed no evidence of reduced megakaryocytopoiesis. The data indicate that in patients with adrenoleukodystrophy treated with GTE platelet counts should be closely monitored because thrombocytopenia may limit the maximal daily intake of GTE.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305837     DOI: 10.1007/BF00190322

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  17 in total

1.  [Adrenoleukodystrophy and adrenomyeloneuropathy--clinical spectrum, pathobiochemical aspects, diagnosis and therapy].

Authors:  S Zierz; W Tackmann
Journal:  Fortschr Neurol Psychiatr       Date:  1989-12       Impact factor: 0.752

2.  Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels.

Authors:  W B Rizzo; M W Phillips; A L Dammann; R T Leshner; S S Jennings; J Avigan; V K Proud
Journal:  Ann Neurol       Date:  1987-03       Impact factor: 10.422

3.  Effects of exogenous monounsaturated fatty acids on fatty acid metabolism in cultured skin fibroblasts from adrenoleukodystrophy patients.

Authors:  R Wilson; D R Tocher; J R Sargent
Journal:  J Neurol Sci       Date:  1992-06       Impact factor: 3.181

4.  Lipoxygenase activity of intact human platelets.

Authors:  M Lagarde; M Croset; D Boukhchache; A Greffe; M Dechavanne; S Renaud
Journal:  Prostaglandins Leukot Med       Date:  1984-01

5.  Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy.

Authors:  R A Knazek; W B Rizzo; J D Schulman; J R Dave
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

6.  Dietary treatment of adrenoleukodystrophy.

Authors:  S Suzuki; T Kobayashi; I Goto; Y Kuroiwa
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

7.  Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.

Authors:  H W Moser; A E Moser; I Singh; B P O'Neill
Journal:  Ann Neurol       Date:  1984-12       Impact factor: 10.422

8.  Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination.

Authors:  C Theda; A B Moser; J M Powers; H W Moser
Journal:  J Neurol Sci       Date:  1992-07       Impact factor: 3.181

9.  Dietary erucic acid therapy for X-linked adrenoleukodystrophy.

Authors:  W B Rizzo; R T Leshner; A Odone; A L Dammann; D A Craft; M E Jensen; S S Jennings; S Davis; R Jaitly; J A Sgro
Journal:  Neurology       Date:  1989-11       Impact factor: 9.910

10.  Adrenoleukodystrophy.

Authors:  H G Lenard
Journal:  Neuropediatrics       Date:  1984-09       Impact factor: 1.947

View more
  7 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Glycerol trioleate/glycerol trierucate therapy in X-linked adrenoleukodystrophy: saturated and unsaturated fatty acids in blood cells. Implications for the follow-up.

Authors:  M Ruiz; T Pampols; M Girós
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 4.  Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders.

Authors:  H W Moser; A B Moser
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

5.  Enhanced lymphocyte proliferation in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.

Authors:  R B Pour; S Stöckler-Ipsiroglu; D H Hunneman; M Gahr; G C Korenke; W Pabst; F Hanefeld; A Peters
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

6.  Hematological and lipid changes in newborn piglets fed milk-replacer diets containing erucic acid.

Authors:  J K Kramer; F D Sauer; E R Farnworth; D Stevenson; G A Rock
Journal:  Lipids       Date:  1998-01       Impact factor: 1.880

7.  Decreased platelet membrane anisotropy in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.

Authors:  S Stöckler; C Opper; A Greinacher; D H Hunneman; G C Korenke; C J Unkrig; F Hanefeld
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.